HERVolution Therapeutics ApS successfully closed an $11.7 million Series A financing round, led by the Serum Institute of India, to accelerate its innovative HERV-targeting immunotherapies.
The funding will support cGMP manufacturing, clinical trials, and pipeline expansion for HERVolution's proprietary approach to harnessing the immune response against dormant human endogenous retroviruses.
CEO J. Robert Coleman stated that they are revolutionizing the treatment of complex age-related diseases by enabling therapeutic targeting of HERVs for the first time.
The company's therapies utilize adenoviral, virus-like particles, and mRNA vectors to create versatile, off-the-shelf treatments for diseases like cancer and type 2 diabetes.
Collection
[
|
...
]